These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 18473811)
1. Targeted therapies in the treatment of renal cell carcinoma. Pezaro C; Davis ID Curr Med Chem; 2008; 15(12):1166-74. PubMed ID: 18473811 [TBL] [Abstract][Full Text] [Related]
2. Evolving role of novel targeted agents in renal cell carcinoma. Hutson TE; Figlin RA Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797 [TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and angiogenic inhibitors in renal cell carcinoma. Sawhney R; Kabbinavar F Curr Urol Rep; 2008 Jan; 9(1):26-33. PubMed ID: 18366971 [TBL] [Abstract][Full Text] [Related]
4. Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review. Badal SAM; Aiken WD; Chin SN Curr Drug Targets; 2017; 18(10):1204-1213. PubMed ID: 27138755 [TBL] [Abstract][Full Text] [Related]
5. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282 [TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic therapy in renal cell cancer. Srinivasan R; Armstrong AJ; Dahut W; George DJ BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927 [TBL] [Abstract][Full Text] [Related]
7. Targeted therapies for kidney cancer in urologic practice. Haas NB; Uzzo RG Urol Oncol; 2007; 25(5):420-32. PubMed ID: 17826664 [TBL] [Abstract][Full Text] [Related]
8. [Effect of angiogenesis inhibitors on renal cell carcinoma]. Bodrogi I Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871 [TBL] [Abstract][Full Text] [Related]
13. Therapy for non-clear cell histologies in renal cancer. Bitting RL; Madden J; Armstrong AJ Curr Clin Pharmacol; 2011 Aug; 6(3):169-80. PubMed ID: 21861801 [TBL] [Abstract][Full Text] [Related]
14. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review. Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391 [TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Zivi A; Cerbone L; Recine F; Sternberg CN Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374 [TBL] [Abstract][Full Text] [Related]
16. VEGF inhibitors in renal cell carcinoma. Vachhani P; George S Clin Adv Hematol Oncol; 2016 Dec; 14(12):1016-1028. PubMed ID: 28212363 [TBL] [Abstract][Full Text] [Related]
17. Recent advances in targeted therapy for renal cell carcinoma. Clark PE Curr Opin Urol; 2007 Sep; 17(5):331-6. PubMed ID: 17762626 [TBL] [Abstract][Full Text] [Related]
18. Novel therapies for renal cell carcinoma. Syed S; Tolcher AW Cancer Treat Res; 2003; 116():227-38. PubMed ID: 14650836 [No Abstract] [Full Text] [Related]
19. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach. Bukowski RM Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712 [TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. Mulders P BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]